Pharmacokinetics and Pharmacodynamics of Clofazimine for Treatment of Cryptosporidiosis
Cindy X. Zhang, Melissa S. Love, Case W. McNamara, Victor Chi, Ashley K. Woods, Sean Joseph, Deborah A. Schaefer, Dana P. Betzer, Michael W. Riggs, Pui-Ying Iroh Tam, Wesley C. Van Voorhis, Samuel L. M. Arnold
Abstract
efficacy. Thus, despite a dosing regimen above the highest doses recommended for mycobacterial therapy, it is very likely the lack of treatment effect in the phase 2a trial was at least partially due to clofazimine concentrations below those required for efficacy against cryptosporidiosis. It is unlikely that clofazimine will provide a remedy for the large number of cryptosporidiosis patients currently without a viable treatment option unless alternative, safe clofazimine formulations with improved oral absorption are developed. (This study has been registered in ClinicalTrials.gov under identifier NCT03341767.).